Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease
Neurology®, 03/13/2012WatabeRudolph M et al. –
Taken together, the findings in this study provide experimental evidence that DNA damage markers are significantly increased in Alzheimer disease (AD) and non–AD dementia. The biomarkers identified outperformed the standard CSF markers for diagnosing AD and non–AD dementia in the cohort investigated.
Here, the authors analyzed the level of novel biomarkers of DNA damage and telomere dysfunction (chitinase activity, N-acetyl-glucosaminidase activity, stathmin, and EF-1 α) in CSF of 94 patients with AD, 41 patients with non-AD dementia, and 40 control patients without dementia.
Enzymatic activity of chitinase (chitotriosidase activity) and stathmin protein level were significantly increased in CSF of patients with AD and non-AD dementia compared with that of no dementia control patients.
As a single marker, chitinase activity was most powerful for distinguishing patients with AD from no dementia patients with an accuracy of 85.8% using a single threshold.
Discrimination was even superior to clinically standard CSF markers that showed an accuracy of 78.4% (β-amyloid) and 77.6% (tau).
Combined analysis of chitinase with other markers increased the accuracy to a maximum of 91%.
The biomarkers of DNA damage were also increased in CSF of patients with non-AD dementia compared with no dementia patients, and the new biomarkers improved the diagnosis of non-AD dementia as well as the discrimination of AD from non-AD dementia.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.